Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition...
Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition...
Enters into North American License and Exclusive Distribution Agreement
TORRANCE, Calif. , Nov. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...
TORRANCE, Calif. , Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing...
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine...
/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...